Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease.

Kai-Ming ChowCheuk Chun SzetoAgnes Shin Man ChoyJack Kit Chung NgAlice Ka Wai MokChi Bon LeungPhilip Kam Tao Li

Published in: The American journal of hospice & palliative care (2019)

High disease burden of palliative care among patients with stage 4 to 5 chronic kidney disease was reflected by transfusion requirement and hospitalization rates, both of which were shown to be significantly ameliorated by ESA treatment.

Keyphrases

palliative care
chronic kidney disease
end stage renal disease
advanced cancer
cardiac surgery
risk factors
stem cells
smoking cessation